2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks

2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks

Making the leap from clinical-stage to the commercial-stage drug isn't easy. It requires an entirely different set of experience to navigate the world of private and public payers and a big investment in sales and marketing to convince doctors to prescribe drugs. In 2018, we'll find out if Keryx Pharmaceuticals (NASDAQ: KERX), Synergy Pharmaceuticals (NASDAQ: SGYP), and Flexion Therapeutics (NASDAQ: FLXN) have what it takes to succeed.

Keryx Pharmaceuticals didn't have a smooth time of it after it won FDA approval of Auryxia in 2014. Despite advantages over existing phosphorous binders that lower phosphorous levels in the body to increase calcium levels in chronic disease patients, sales have been slow to grow. Auryxia recorded only $27.2 million in revenue in 2016.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com